INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 438m ago
HOUSE PTR38m ago
SEC 13F38m ago
ROBINHOOD CHAIN38m ago
Corporate insider
UM

Urist Marshall

EVP, Research & InvestmentsCIK 0001838139

EDGAR filingsOpen in network
Disclosed transactions15
Buys / sells0 / 9
Max Insider Score33
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
18
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$239K
4,126 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Royalty Pharma plcEVP, Research & Investments · Nov 7, 2025
2
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A
—
8,252 sh
Aug 5, 2026
Aug 7, 2026
traded Aug 5, 2026
+2d
SEC FORM 4

Evidence

5
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Gift
G—
3,000 sh
Aug 7, 2026Aug 7, 2026
traded Aug 7, 2026
+0dSEC FORM 4

Evidence

17
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$502K
9,098 sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC FORM 4

Evidence

14
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A—
20.0K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

21
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$805K
20.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

20
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$790K
20.0K sh
Jan 16, 2026Jan 20, 2026
traded Jan 16, 2026
+4dSEC FORM 4

Evidence

20
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$816K
20.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$786K
20.0K sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC FORM 4

Evidence

16
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$768K
20.0K sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

25
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$914K
23.3K sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

33
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$714K
18.2K sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

13
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Derivative conversion
C—
16.0K sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

21
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Derivative conversion
C—
160.0K sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

13
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A—
4,626 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence